Showing results (1921-1930 of 2,084) with videos related to

Sort By:
Pageof 209
Blood Cancer Journal|November 10, 2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsA Castellino, A Chiappella, B R LaPlant, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
American Journal of Hematology|March 4, 2021
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphomaMatthew J Maurer, Lasse H Jakobsen, Raphael Mwangi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2012
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsJun Y Axup, Krishna M Bajjuri, Melissa Ritland, et al.
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
Hematological Oncology|November 29, 2024
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment ResistanceAllison M Bock, Kerstin Wenzl, Joseph P Novak, et al.
Hematological Oncology|May 31, 2023
Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomasMelissa A Hopper, Kerstin Wenzl, Keenan T Hartert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2026
Optimizing low dose radiotherapy for indolent lymphomas: comparing 8 Gy in 2 fractions to 4 Gy in 2 fractionsJessica F Burlile, William S Harmsen, Sydney D Suddendorf, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2022
Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivoTobias Lange, Ursula Valentiner, Daniel Wicklein, et al.
Journal of Medicinal Chemistry|December 15, 2010
Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymeraseFrank Narjes, Benedetta Crescenzi, Marco Ferrara, et al.
Pageof 209